Bimuno GOS and Probi Defendum increase SCFAs in new synbiotic research

Published: 16-Apr-2024

The combination becomes one of the first commercially available synbiotics with this scientific confirmation

In an exciting step forward for the growing synbiotic category, a new study has demonstrated selective utilisation in a commercially available synbiotic combination created through the partnership of Clasado Biosciences and Probi AB.

The research project evaluates the synergistic potential of Bimuno GOS and Probi Defendum, a combination designed to support immune health formulations, and also explored the complementary synbiotic combination of Bimuno GOS and Probi Digestis, a gastrointestinal focused concept supported by a collective publication count of 350.

The study, “A Novel Synbiotic Blend of Galactooligosaccharide (GOS) and a Two-Strain Probiotic Acts Synergistically to Increase Lactate and Short-Chain Fatty Acid Production in a Short-Term ex vivo Colon Fermentation Model," has been published in the International Journal of Nutritional Sciences.

The study validates that the Probi Defendum probiotic was able to selectively utilise Bimuno GOS for growth, highlighting substrate specificity for Probi’s probiotic strains L. plantarum HEAL9 (HEAL9) and L. paracasei 8700:2.

The combination was shown to significantly increase lactate levels and increase short chain fatty acid (SCFA) butyrate by 26% when Bimuno GOS was co-supplemented in combination with Probi Defendum.

Crucially, both synbiotic concepts showed no increase in gas production, highlighting good tolerability in the combinations.

Dr Lucien Harthoorn, Clasado’s R&D Director and lead author of the study commented: “We cannot overstate how valuable this study is to the rapidly growing synbiotic industry."

"The results show a validated synergistic effect in a commercially available synbiotic combination, increasing lactate and butyrate, two important gut health-promoting components that are also associated with supporting immune health.”

The study’s findings highlight significant potential for the development of synbiotic products aimed at promoting gut health and overall wellbeing, as well as products designed to support immune function.

To learn more about the synbiotic combinations developed by Clasado and Probi AB, click here

You may also like